The epidermal growth factor receptor (EGFR) is recognized as an important molecular target in cancer therapy, and somatic activating mutations of the EGFR gene (EGFR mutations) are known as one of the oncogenic driver mutations in non small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and cancer.